GlassScriptPhysician profile
Muhammad J Sethi
NPI 1275762130
$669,855.14
in general payments reported to CMS, 2019-2025
27 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389K · 2020: $104K · 2021: $65K · 2022: $64K · 2023: $13K · 2024: $10K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Travel and Lodging: $3,618 · Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,677.00 |
| Travel and Lodging | $3,618.39 |
| Food and Beverage | $1,596.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $232,766.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $178,430.85 | 2019-2025 | Evenity, Tepezza |
| Lilly USA, LLC | $133,990.53 | 2019-2020 | |
| Shire North American Group INC | $67,573.79 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,380.22 | 2019 | |
| Amarin Pharma, INC. | $22,181.02 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $7,886.30 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $3,566.63 | 2019-2023 | |
| Sequel Med Tech, LLC | $184.44 | 2025 | Twiist |
| Dexcom, INC. | $155.06 | 2021-2022 | |
| Abbvie INC. | $126.38 | 2021-2023 | Linzess, Creon |
| Horizon Therapeutics Plc | $99.37 | 2019-2023 | Tepezza |
| Mannkind Corporation | $96.36 | 2019-2020 | |
| Abbott Laboratories | $69.70 | 2022-2023 | Freestyle Libre 2 |
| Nestle Healthcare Nutrition INC. | $46.74 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $42.47 | 2022-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $38.21 | 2021-2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $36.46 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $35.87 | 2025 | |
| Antares Pharma, INC. | $32.31 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $27.29 | 2019 | |
| Merck Sharp & Dohme LLC | $23.65 | 2019 | |
| Radius Health, INC. | $17.89 | 2020 | |
| Ascensia Diabetes Care US INC. | $16.83 | 2023 | |
| Esperion Therapeutics, INC. | $15.81 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.35 | 2023 | Unithroid |
| Travere Therapeutics, INC. | $1.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Sethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.